Related Experiment Video
Updated: Jun 22, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Methylphenidate has positive hypocholesterolemic and hypotriglyceridemic effects: new data.
Gideon Charach1, Nehemia Kaysar, Itamar Grosskopf
1Department of Internal Medicine C, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6 Weizman Street, Tel Aviv 64239, Israel. drcharach@012.net.il
Journal of Clinical Pharmacology
|June 26, 2009
Summary
Methylphenidate, a stimulant for attention-deficit hyperactivity disorder (ADHD), was found to improve plasma lipid profiles. This study shows methylphenidate decreases total cholesterol, LDL-C, triglycerides, and lipoprotein (a) in ADHD patients.
Area of Science:
- Pharmacology
- Biochemistry
- Psychiatry
Background:
- Psychotropic medications can alter plasma lipid profiles.
- Methylphenidate, a central nervous system stimulant, has an uninvestigated effect on lipid metabolism.
Purpose of the Study:
- To evaluate the impact of methylphenidate on plasma lipid profiles in patients with attention-deficit hyperactivity disorder (ADHD).
Main Methods:
- Blood samples from 42 ADHD patients were analyzed before and after 3 months of methylphenidate treatment.
- Measurements included total cholesterol, LDL-C, HDL-C, triglycerides, apolipoproteins A and B, and lipoprotein (a).
Main Results:
- Methylphenidate significantly decreased total cholesterol (-9 mg/dL), LDL-C (-5.0 mg/dL), triglycerides (-8.0 mg/dL), and lipoprotein (a) (-2.0 mg/dL).
- No significant changes were observed in HDL-C, apolipoprotein A, or apolipoprotein B levels.
Conclusions:
- Methylphenidate treatment positively impacts the lipid profile in ADHD patients.
- The drug effectively reduces key lipid markers, including total cholesterol, LDL-C, triglycerides, and lipoprotein (a).
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:24Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:28Adrenergic Agonists: Mixed-Action Agents
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...